Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

964 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identification of novel selective V2 receptor non-peptide agonists.
Del Tredici AL, Vanover KE, Knapp AE, Bertozzi SM, Nash NR, Burstein ES, Lameh J, Currier EA, Davis RE, Brann MR, Mohell N, Olsson R, Piu F. Del Tredici AL, et al. Among authors: davis re. Biochem Pharmacol. 2008 Oct 30;76(9):1134-41. doi: 10.1016/j.bcp.2008.08.004. Epub 2008 Aug 12. Biochem Pharmacol. 2008. PMID: 18761325
Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist.
Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, Del Tredici AL, Piu F, Schiffer HH, Ott TR, Burstein ES, Uldam AK, Thygesen MB, Schlienger N, Andersson CM, Son TY, Harvey SC, Powell SB, Geyer MA, Tolf BR, Brann MR, Davis RE. Vanover KE, et al. Among authors: davis re. J Pharmacol Exp Ther. 2006 May;317(2):910-8. doi: 10.1124/jpet.105.097006. Epub 2006 Feb 9. J Pharmacol Exp Ther. 2006. PMID: 16469866
Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist.
Burstein ES, Ma J, Wong S, Gao Y, Pham E, Knapp AE, Nash NR, Olsson R, Davis RE, Hacksell U, Weiner DM, Brann MR. Burstein ES, et al. Among authors: davis re. J Pharmacol Exp Ther. 2005 Dec;315(3):1278-87. doi: 10.1124/jpet.105.092155. Epub 2005 Aug 31. J Pharmacol Exp Ther. 2005. PMID: 16135699
Structural requirements of transmembrane domain 3 for activation by the M1 muscarinic receptor agonists AC-42, AC-260584, clozapine, and N-desmethylclozapine: evidence for three distinct modes of receptor activation.
Spalding TA, Ma JN, Ott TR, Friberg M, Bajpai A, Bradley SR, Davis RE, Brann MR, Burstein ES. Spalding TA, et al. Among authors: davis re. Mol Pharmacol. 2006 Dec;70(6):1974-83. doi: 10.1124/mol.106.024901. Epub 2006 Sep 7. Mol Pharmacol. 2006. PMID: 16959945
AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model.
Bradley SR, Lameh J, Ohrmund L, Son T, Bajpai A, Nguyen D, Friberg M, Burstein ES, Spalding TA, Ott TR, Schiffer HH, Tabatabaei A, McFarland K, Davis RE, Bonhaus DW. Bradley SR, et al. Among authors: davis re. Neuropharmacology. 2010 Feb;58(2):365-73. doi: 10.1016/j.neuropharm.2009.10.003. Epub 2009 Oct 14. Neuropharmacology. 2010. PMID: 19835892
The role of M1 muscarinic receptor agonism of N-desmethylclozapine in the unique clinical effects of clozapine.
Weiner DM, Meltzer HY, Veinbergs I, Donohue EM, Spalding TA, Smith TT, Mohell N, Harvey SC, Lameh J, Nash N, Vanover KE, Olsson R, Jayathilake K, Lee M, Levey AI, Hacksell U, Burstein ES, Davis RE, Brann MR. Weiner DM, et al. Among authors: davis re. Psychopharmacology (Berl). 2004 Dec;177(1-2):207-16. doi: 10.1007/s00213-004-1940-5. Epub 2004 Jul 16. Psychopharmacology (Berl). 2004. PMID: 15258717
Pharmacological characterization of AC-90179 [2-(4-methoxyphenyl)-N-(4-methyl-benzyl)-N-(1-methyl-piperidin-4-yl)-acetamide hydrochloride]: a selective serotonin 2A receptor inverse agonist.
Vanover KE, Harvey SC, Son T, Bradley SR, Kold H, Makhay M, Veinbergs I, Spalding TA, Weiner DM, Andersson CM, Tolf BR, Brann MR, Hacksell U, Davis RE. Vanover KE, et al. Among authors: davis re. J Pharmacol Exp Ther. 2004 Sep;310(3):943-51. doi: 10.1124/jpet.104.066688. Epub 2004 Apr 21. J Pharmacol Exp Ther. 2004. PMID: 15102927
ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models.
Gardell LR, Vanover KE, Pounds L, Johnson RW, Barido R, Anderson GT, Veinbergs I, Dyssegaard A, Brunmark P, Tabatabaei A, Davis RE, Brann MR, Hacksell U, Bonhaus DW. Gardell LR, et al. Among authors: davis re. J Pharmacol Exp Ther. 2007 Aug;322(2):862-70. doi: 10.1124/jpet.107.121715. Epub 2007 May 22. J Pharmacol Exp Ther. 2007. PMID: 17519387
964 results